News | March 28, 2022
Tata Capital Healthcare Fund II raises Rs 955 crore
The fund will take equity positions in India-focused healthcare and life sciences-related companies
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
Data to establish the safety profile and human dose of vaccine candidate
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
Subscribe To Our Newsletter & Stay Updated
